Gen­mab gains on promis­ing ear­ly suc­cess for dara­tu­mum­ab PhI­II in mul­ti­ple myelo­ma, but ques­tions linger

Shares of Copen­hagen-based Gen­mab surged Thurs­day morn­ing as in­ves­ti­ga­tors de­clared that its late-stage com­bo drug us­ing dara­tu­mum­ab (Darza­lex) hit the pri­ma­ry end­point for treat­ing mul­ti­ple myelo­ma as a front­line ther­a­py at the in­ter­im read­out stage. Re­searchers now plan to un­blind the da­ta as Gen­mab {CPH: $GEN} and J&J $JNJ hus­tle along with a new mar­ket­ing ap­pli­ca­tion.

Gen­mab shares $GEN shot up 8% on the news.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER